Arcadia Biosciences (NASDAQ:RKDA) Earns Daily Media Sentiment Score of 0.21

News coverage about Arcadia Biosciences (NASDAQ:RKDA) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arcadia Biosciences earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the basic materials company an impact score of 45.9048037707433 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several equities research analysts recently commented on RKDA shares. ValuEngine cut Arcadia Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. Piper Jaffray set a $20.00 price target on Arcadia Biosciences and gave the company a “hold” rating in a research note on Wednesday, March 14th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ RKDA traded down $0.56 during trading hours on Friday, hitting $24.34. The stock had a trading volume of 115,954 shares, compared to its average volume of 1,612,730. Arcadia Biosciences has a 52 week low of $3.60 and a 52 week high of $66.56. The stock has a market cap of $61.78, a price-to-earnings ratio of -3.55 and a beta of -5.79.

Arcadia Biosciences (NASDAQ:RKDA) last posted its earnings results on Tuesday, March 20th. The basic materials company reported ($1.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.00) by $0.61. Arcadia Biosciences had a negative return on equity of 121.31% and a negative net margin of 390.14%. The firm had revenue of $1.43 million during the quarter.

In other news, Director Eric J. Rey sold 21,255 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $45.38, for a total transaction of $964,551.90. Following the completion of the transaction, the director now directly owns 28,340 shares in the company, valued at $1,286,069.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Eric J. Rey sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, March 23rd. The stock was sold at an average price of $33.44, for a total value of $167,200.00. Following the transaction, the director now owns 12,335 shares of the company’s stock, valued at $412,482.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,005 shares of company stock valued at $1,189,047. Corporate insiders own 25.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Arcadia Biosciences (NASDAQ:RKDA) Earns Daily Media Sentiment Score of 0.21” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/arcadia-biosciences-rkda-receiving-somewhat-positive-press-coverage-report-shows.html.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market.

Insider Buying and Selling by Quarter for Arcadia Biosciences (NASDAQ:RKDA)

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply